BenevolentAI | Results Presentation Deck

The slide uses a hub-and-spoke diagram to show the central platform capabilities branching into different commercialization strategies.present_solution

Open slide detail

front_matter

Open slide detail

The table presents financial data in £'000s. Footnotes clarify exclusions related to Business Combination.analyze_data

Open slide detailBeat · Financials

The table details specific non-recurring costs related to a Business Combination, including share-based payments and impairment of assets.analyze_data

Open slide detailBeat · Financials

The slide provides a bridge between operating loss and cash flow, with explanatory notes on the right side.analyze_data

Open slide detailBeat · Financials

The slide uses a hub-and-spoke diagram to link the company to its capital allocation priorities.quantify_opportunity

Open slide detailBeat · Financials

transition

Open slide detailBeat · Traction

The chart uses a horizontal bar format to show progression through Target ID, Lead Opt, Preclinical, Phase I, and Phase II.analyze_data

Open slide detailBeat · Traction

The slide uses a treatment flow diagram to show where BEN-2293 fits relative to existing therapies.present_solution

Open slide detailBeat · SolutionLoop · Quick Win Big Bet

The slide uses a process-flow style layout to connect study design to efficacy outcomes.present_framework

Open slide detailBeat · SolutionLoop · Quick Win Big Bet

Includes clinical trial timeline and strategic intent for partnership.plan_implementation

Open slide detailBeat · SolutionLoop · Quick Win Big Bet

The slide contrasts the market size and unmet needs of UC with the specific mechanism and target patient population for BEN-8744.diagnose_problem

Open slide detailBeat · ProblemLoop · Cost Of Inaction

The slide uses a combination of a process diagram and dose-response/bar charts to validate the drug's mechanism and potency.analyze_data

Open slide detailBeat · ProblemLoop · Cost Of Inaction

The slide uses a timeline at the top and a three-column structure below to detail specific achievements in drug development.summarize

Open slide detailLoop · Cost Of Inaction

transition

summarize

state_next_steps

appendix

The slide is split into two sections: team composition on the left and board members on the right.introduce_nominees

Open slide detail

summarize

Open slide detail

The slide uses a horizontal timeline structure to map specific drug program milestones (BEN-2293, BEN-8744, BEN-28010) against broader strategic goals.plan_implementation

Open slide detail

The slide uses a complex biological diagram to map the roles of Trk receptors in the skin layers and immune response.present_solution

Open slide detail

Includes a biological diagram of skin layers and immune cell interactions.summarize

Open slide detail

Includes dose-response curves for cytokine inhibition and mouse ear inflammation reduction.summarize

Open slide detail

The slide uses a flow-chart to represent an adaptive clinical trial design.illustrate_case

Open slide detail

The chart displays efficacy trends for different dosing regimens of BEN-2293 compared to placebo.analyze_data

Open slide detail

Includes a pathway diagram, a volcano plot for differential expression, and a tissue-specific RNAseq expression profile.diagnose_problem

Open slide detail

The slide uses a causal chain framework to link PDE10 inhibition to therapeutic outcomes in IBD.present_solution

Open slide detail

The slide uses a split-layout with a summary of the partnership on the left and a timeline/milestone callout on the right.illustrate_case

Open slide detail

The slide is split into two main sections: a case study on baricitinib/FDA approval and a sidebar on a DNDi partnership.illustrate_case

Open slide detail

The slide uses a 2x2 matrix to map specific companies like BenevolentAI, Recursion, Exscientia, Schrodinger, and Relay Therapeutics.present_framework

Open slide detail